Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Repare Therapeutics Inc (NQ: RPTX ) 3.090 +0.080 (+2.66%) Streaming Delayed Price Updated: 11:58 AM EDT, Aug 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Repare Therapeutics Inc < Previous 1 2 3 Next > Repare Therapeutics Inc. (NASDAQ: RPTX) Near the Top of Equities by Percentage Gain on 8/10 August 10, 2023 Via Investor Brand Network Repare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results August 09, 2023 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference June 08, 2023 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials June 07, 2023 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid Tumors June 06, 2023 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights June 02, 2023 From Repare Therapeutics Inc. Via Business Wire Repare Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) May 22, 2023 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results May 09, 2023 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors April 28, 2023 From Repare Therapeutics Inc. Via Business Wire NASDAQ: RPTX Investor Alert: Investigation over Potential Wrongdoing at Repare Therapeutics Inc. April 28, 2023 San Diego, CA -- (SBWIRE) -- 04/28/2023 -- Certain directors of Repare Therapeutics Inc. are under investigation over potential breaches of fiduciary duties. Via SBWire Repare Therapeutics Presents Initial Clinical Data from the Phase 1/2 TRESR and ATTACC Trials Evaluating Camonsertib in Combination with Three PARP Inhibitors at the 2023 AACR Annual Meeting April 18, 2023 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Announces Plenary Oral Presentation at the 2023 AACR Annual Meeting on Camonsertib and Additional Data Presentations on RP-6306 March 14, 2023 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results February 28, 2023 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Inc. (NASDAQ:RPTX) Investor Investigation over Possible Violations of Securities Laws February 22, 2023 San Diego, CA -- (SBWIRE) -- 02/22/2023 -- An investigation shares over potential securities laws violations by Repare Therapeutics Inc. Via SBWire Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Repare Therapeutics Inc. (RPTX) Investigation February 08, 2023 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire Repare Therapeutics to Participate in Two Upcoming Investor Conferences February 02, 2023 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Receives $1.5 Million (¥200 million) Payment from Ono Pharmaceuticals January 19, 2023 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans December 19, 2022 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results November 09, 2022 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics to Participate in Two Upcoming Investor Conferences November 07, 2022 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics to Participate in Two Upcoming Investor Conferences September 07, 2022 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results August 04, 2022 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics to Participate at the Goldman Sachs 43rd Annual Global Healthcare Conference June 07, 2022 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500) June 01, 2022 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics to Participate at the 2022 Guggenheim Synthetic Lethality Day May 09, 2022 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results May 05, 2022 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Announces Publication of Preclinical Data in Nature Demonstrating the Potential of PKMYT1 Inhibitor RP-6306 in Tumors With CCNE1 Amplification April 20, 2022 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Presents Updated Clinical Data from the Ongoing Phase 1/2 TRESR Study of RP-3500 Monotherapy in Solid Tumors at the 2022 AACR Annual Meeting April 11, 2022 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics to Present New Clinical and Preclinical Data at the 2022 AACR Annual Meeting April 08, 2022 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics to Participate in Two Upcoming Virtual Investor Conferences February 03, 2022 From Repare Therapeutics Inc. Via Business Wire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.